Association Between the Frailty and Cognitive Impairment Among Patients With Hypertension-A Post Hoc Analysis of the SPRINT Trial.
frailty
hypertension
intensive blood pressure control
mild cognitive impairment
probable dementia
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
04 04 2023
04 04 2023
Historique:
medline:
5
4
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Background Frailty and cognitive impairment are common in the elderly, with various shared risk factors like hypertension. Frailty is a marker for future cognitive function. Moreover, whether intensive blood pressure interacted with frailty and cognitive impairment is unknown. Methods and Results We performed a post hoc analysis of data from SPRINT (Systolic Blood Pressure Intervention Trial). The relationship between frailty and a composite of probable dementia (PD) and mild cognitive impairment (MCI) was analyzed. Also, we evaluated the interaction of intensive blood pressure lowering in the relationship between frailty and cognitive impairment. A total of 8537 patients were included in our study, and 35.1% were women. The mean age of these participants was 67.9±9.3 years. According to the baseline frailty index, 1670, 4637, and 2230 patients were in fit, less fit, and frail statuses, respectively. During a mean follow-up of 4.61 years, 871 cases of PD or MCI occurred. Compared with those in fit status, those with less fit (hazard ratio [HR], 2.14 [95% CI, 1.65-2.77]) and frailty (HR, 4.28 [95% CI, 3.26-5.61]) status had a higher incidence of a composite of PD and MCI. Blood pressure control strategy interacted with the correlation between frailty and cognitive impairment. Intensive blood pressure control (HR, 2.4 [95% CI, 2.0-2.8]) accelerated the relationship between frailty and incidence of PD and MCI compared with the standard treatment group (HR, 1.8 [95% CI, 1.5-2.1];
Identifiants
pubmed: 36974773
doi: 10.1161/JAHA.122.028736
pmc: PMC10122877
doi:
Substances chimiques
Antihypertensive Agents
0
Banques de données
ClinicalTrials.gov
['NCT01206062']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028736Références
Clin Trials. 2014 Oct;11(5):532-46
pubmed: 24902920
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):343-350
pubmed: 34933996
BMC Med. 2021 Oct 18;19(1):248
pubmed: 34657626
J Ambul Care Manage. 2006 Oct-Dec;29(4):310-9
pubmed: 16985389
J Am Geriatr Soc. 2020 Mar;68(3):496-504
pubmed: 31840813
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Panminerva Med. 2012 Sep;54(3):179-88
pubmed: 22801435
Ageing Res Rev. 2013 Sep;12(4):840-51
pubmed: 23831959
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA Intern Med. 2014 Mar;174(3):324-33
pubmed: 24493100
BMC Neurol. 2018 Nov 26;18(1):193
pubmed: 30477436
Lancet Public Health. 2022 Feb;7(2):e105-e125
pubmed: 34998485
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):738-43
pubmed: 17634321
Arch Intern Med. 2002 Oct 14;162(18):2046-52
pubmed: 12374512
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
J Gerontol A Biol Sci Med Sci. 2021 May 22;76(6):1134-1143
pubmed: 33420508
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Gerontol A Biol Sci Med Sci. 2016 May;71(5):649-55
pubmed: 26755682
Int Psychogeriatr. 2021 Oct;33(10):1035-1043
pubmed: 33586645
Lancet Neurol. 2008 Aug;7(8):683-9
pubmed: 18614402
J Am Med Dir Assoc. 2022 Nov;23(11):1807-1814
pubmed: 35283085
J Am Med Dir Assoc. 2016 Oct 1;17(10):881-8
pubmed: 27324809
Alzheimers Res Ther. 2015 Aug 03;7(1):54
pubmed: 26240611
JAMA. 2019 Feb 12;321(6):553-561
pubmed: 30688979
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272